Deletion of low molecular weight protein tyrosine phosphatase (Acp1) protects against stress-induced cardiomyopathy

    loading  Checking for direct PDF access through Ovid

Abstract

The low molecular weight protein tyrosine phosphatase (LMPTP), encoded by theACP1gene, is a ubiquitously expressed phosphatase whosein vivofunction in the heart and in cardiac diseases remains unknown. To investigate thein vivorole of LMPTP in cardiac function, we generated mice with genetic inactivation of theAcp1locus and studied their response to long-term pressure overload.Acp1−/−mice develop normally and ageing mice do not show pathology in major tissues under basal conditions. However,Acp1−/−mice are strikingly resistant to pressure overload hypertrophy and heart failure. Lmptp expression is high in the embryonic mouse heart, decreased in the postnatal stage, and increased in the adult mouse failing heart. We also show that LMPTP expression increases in end-stage heart failure in humans. Consistent with their protected phenotype,Acp1−/−mice subjected to pressure overload hypertrophy have attenuated fibrosis and decreased expression of fibrotic genes. Transcriptional profiling and analysis of molecular signalling show that the resistance ofAcp1−/−mice to pathological cardiac stress correlates with marginal re-expression of fetal cardiac genes, increased insulin receptor beta phosphorylation, as well as PKA and ephrin receptor expression, and inactivation of the CaMKIIδ pathway. Our data show that ablation of Lmptp inhibits pathological cardiac remodelling and suggest that inhibition of LMPTP may be of therapeutic relevance for the treatment of human heart failure. © 2015 The Authors.The Journal of Pathologypublished by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Related Topics

    loading  Loading Related Articles